secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001104659-23-056018
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q1 net loss $33.7M; positive Phase 2b data for JNJ-2113; cash runway to 2025
--------------------------------------------------------------------------------

- Net loss $33.7M ($0.67/share) vs $20.9M loss in Q1 2022; license revenue zero (prior year $25.7M milestone).
- Positive Phase 2b FRONTIER 1 topline data for JNJ-2113 in psoriasis: PASI-75 met across all dose groups vs placebo.
- Phase 2 REVIVE rusfertide data: 69.2% responders vs 18.5% placebo (p=0.0003); phlebotomy free 92.3% vs placebo.
- Closed public offering of 5.75M shares at $20 each; net proceeds $108.1M; cash runway now through end of 2025.
- Cash and marketable securities $230.8M; R&D expenses $27.4M (down from $36.3M); G&A $8.6M (down from $10.5M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923056018/0001104659-23-056018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923056018/tm2314649d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-056018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer